Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors-Reference-Cited by-同舟云学术

Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors

Published:2016-11 Issue:21 Volume:26 Page:5222-5228
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Jadhavar Pradeep S.,Ramachandran Sreekanth A.,Riquelme Eduardo,Gupta Ashu,Quinn Kevin P.,Shivakumar Devleena,Ray Soumya,Zende Dnyaneshwar,Nayak Anjan K.,Miglani Sandeep K.,Sathe Balaji D.,Raja Mohd.^ORCID,Farias Olivia,Alfaro Ivan,Belmar Sebastián^ORCID,Guerrero Javier,Bernales Sebastián,Chakravarty Sarvajit,Hung David T.,Lindquist Jeffrey N.,Rai Roopa^ORCID

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference34 articles.

1. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma

2. Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer

3. Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors

4. New and emerging HDAC inhibitors for cancer treatment

5. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer;Oncogene;2024-09-13

2. Advances in dual-targeting inhibitors of HDAC6 for cancer treatment;European Journal of Medicinal Chemistry;2024-09

3. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer;2024-05-07

4. Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer;Frontiers in Chemistry;2022-08-12

5. Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat;Bioorganic & Medicinal Chemistry Letters;2022-01